AspenBio Pharma Inc.
1585 South Perry Street
Castle Rock,
CO 80104
United States - Map
Phone: 303-794-2000
Fax: 303-798-8332
Web Site: http://www.aspenbiopharma.com
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | 24 |
|
| AspenBio Pharma, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of drugs and diagnostics for human and animal healthcare. Its product pipeline includes AppyScore, which has completed 800 patient pivotal clinical trials for use as an aid in the diagnosis of appendicitis. The company also develops animal healthcare products focusing on reproduction, including BoviPure LH, a recombinant hormone analog that induces ovulation and reduces the risk of pregnancy loss in dairy cows; BoviPure FSH, a single-chain bovine FSH analog for super-ovulation of cows; EquiPure LH, a single-chain LH analog for horses that stimulates follicular development, as well as induces ovulation in estrous mares; and EquiPure FSH, a single-chain FSH analog for horses that assists mares through transition and for super-ovulation. In addition, it manufactures and markets approximately 20-30 purified protein products primarily for use as controls by diagnostic test kit manufacturers and research facilities to determine whether diagnostic test kits are functioning properly. The company was founded in 2000 and is based in Castle Rock, Colorado. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Daryl J. Faulkner , 60
Exec. Chairman and Chief Exec. Officer |
$
0 |
$
0 | Mr. Gregory Pusey , 56
Vice Chairman and Sec. |
$
150.00K | N/A | Mr. Jeffrey G. McGonegal , 57
Chief Financial Officer and Principal Accounting Officer |
$
110.00K |
$
0 | Dr. Mark A. Colgin Ph.D, 40
Chief Scientific Officer |
$
151.00K |
$
0 | Mr. Richard G. Donnelly , 50
Consultant |
$
287.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.39% Nasdaq 
0.11%
Profile
